ADAM17 and metastatic malignant neoplasm in the lymph nodes: The meta-analysis revealed that lower ADAM17 levels were correlated with longer overall survival rates in GC, while ADAM17 overexpression was associated with an advanced TNM stage and the presence of lymph node metastasis.